NURP 532 Advanced Pharma-
cotherapeutics: Comprehensive Practice
Exam
Total Questions: 150 \2026|2027
1. A patient with liver cirrhosis is prescribed a medication that undergoes extensive first-pass
metabolism. How should the NP anticipate adjusting the dosage?
A. Increase the dose to overcome metabolism
B. Decrease the dose to prevent toxicity
C. No change is needed
D. Switch to intravenous only
Correct Answer: B
Rationale: In liver cirrhosis, hepatic function is reduced, decreasing first-pass metabolism. This leads to
higher bioavailability of oral medications, increasing the risk of toxicity. Doses should generally be
decreased.
2. Which of the following best describes the therapeutic index of a drug?
A. The time it takes for the drug to reach peak concentration
B. The ratio between the toxic dose and the therapeutic dose
C. The percentage of drug bound to plasma proteins
D. The rate at which the drug is excreted by the kidneys
Correct Answer: B
Rationale: The therapeutic index is the ratio of the dose that produces toxicity to the dose that produces
a clinically desired or effective response. A narrow therapeutic index requires close monitoring (e.g.,
Warfarin, Digoxin).
3. A patient is taking Drug A (highly protein-bound) and Drug B is added (also highly protein-bound).
What is the primary concern?
A. Decreased absorption of Drug A
B. Increased free fraction of Drug A leading to toxicity
C. Reduced renal excretion of Drug B
D. Competitive inhibition of CYP450
,Correct Answer: B
Rationale: When two highly protein-bound drugs compete for binding sites, one may be displaced,
increasing the free (active) fraction of the drug in the plasma, potentially leading to toxicity.
4. Which phase of FDA drug approval involves post-marketing surveillance?
A. Phase I
B. Phase II
C. Phase III
D. Phase IV
Correct Answer: D
Rationale: Phase IV occurs after the drug is approved and on the market. It involves monitoring for long-
term adverse effects and effectiveness in larger populations.
5. An NP prescribes a medication that is a CYP450 3A4 inhibitor. What effect will this have on a
concomitant medication metabolized by 3A4?
A. Decreased levels of the concomitant medication
B. Increased levels of the concomitant medication
C. No effect on metabolism
D. Increased excretion of the concomitant medication
Correct Answer: B
Rationale: Inhibitors slow down the metabolism of substrates. If Drug A inhibits the enzyme that
metabolizes Drug B, levels of Drug B will rise, increasing toxicity risk.
6. What is the definition of "off-label" prescribing?
A. Prescribing a generic version of a brand drug
B. Prescribing a drug for a use not approved by the FDA
C. Prescribing a controlled substance without a DEA number
D. Prescribing a drug past its expiration date
Correct Answer: B
Rationale: Off-label prescribing involves using an FDA-approved medication for an indication, dosage, or
population not specified in the official labeling. It is legal and common in NP practice if supported by
evidence.
7. Which route of administration bypasses the first-pass effect completely?
,A. Oral
B. Sublingual
C. Intravenous
D. Rectal
Correct Answer: C
Rationale: Intravenous administration delivers the drug directly into systemic circulation, bypassing the
GI tract and liver first-pass metabolism entirely. Sublingual bypasses most, but IV bypasses all.
8. A patient has a GFR of 25 mL/min. How does this affect drug prescribing?
A. Increase doses of renally excreted drugs
B. Decrease doses or extend intervals of renally excreted drugs
C. Avoid all oral medications
D. No adjustment needed for antibiotics
Correct Answer: B
Rationale: A GFR of 25 indicates severe renal impairment. Drugs excreted by the kidneys will
accumulate, requiring dose reduction or interval extension to prevent toxicity.
9. What is the primary goal of Phase I clinical trials?
A. Efficacy in disease state
B. Safety and dosage in healthy volunteers
C. Comparison with standard treatment
D. Long-term side effect monitoring
Correct Answer: B
Rationale: Phase I trials primarily assess safety, tolerability, and pharmacokinetics in a small group of
healthy volunteers.
10. Which of the following is a Black Box Warning?
A. A warning about minor side effects
B. The FDA's strongest warning regarding serious risks
C. A warning for pediatric use only
D. A warning regarding cost
Correct Answer: B
, Rationale: A Black Box Warning is the strictest warning put in the labeling of prescription drugs by the
FDA, indicating a significant risk of serious or life-threatening adverse effects.
11. Bioequivalence between two drugs means:
A. They contain the same inactive ingredients
B. They have the same bioavailability and rate of absorption
C. They are manufactured by the same company
D. They cost the same amount
Correct Answer: B
Rationale: Bioequivalent drugs have the same rate and extent of absorption of the active ingredient,
resulting in similar therapeutic effects.
12. A patient develops a rash after starting Penicillin. This is an example of:
A. A side effect
B. An allergic reaction (Idiosyncratic)
C. A teratogenic effect
D. A drug-drug interaction
Correct Answer: B
Rationale: A rash following penicillin is typically an immunologic allergic reaction, distinct from a
predictable side effect like nausea.
13. Which factor most influences drug distribution in the elderly?
A. Increased total body water
B. Decreased body fat
C. Decreased albumin levels
D. Increased liver mass
Correct Answer: C
Rationale: Elderly patients often have decreased serum albumin, leading to less protein binding and
higher levels of free drug for highly bound medications.
14. What is the "half-life" of a drug?
A. Time to reach peak concentration
B. Time required to eliminate 50% of the drug from the body
C. Time until the drug becomes ineffective
cotherapeutics: Comprehensive Practice
Exam
Total Questions: 150 \2026|2027
1. A patient with liver cirrhosis is prescribed a medication that undergoes extensive first-pass
metabolism. How should the NP anticipate adjusting the dosage?
A. Increase the dose to overcome metabolism
B. Decrease the dose to prevent toxicity
C. No change is needed
D. Switch to intravenous only
Correct Answer: B
Rationale: In liver cirrhosis, hepatic function is reduced, decreasing first-pass metabolism. This leads to
higher bioavailability of oral medications, increasing the risk of toxicity. Doses should generally be
decreased.
2. Which of the following best describes the therapeutic index of a drug?
A. The time it takes for the drug to reach peak concentration
B. The ratio between the toxic dose and the therapeutic dose
C. The percentage of drug bound to plasma proteins
D. The rate at which the drug is excreted by the kidneys
Correct Answer: B
Rationale: The therapeutic index is the ratio of the dose that produces toxicity to the dose that produces
a clinically desired or effective response. A narrow therapeutic index requires close monitoring (e.g.,
Warfarin, Digoxin).
3. A patient is taking Drug A (highly protein-bound) and Drug B is added (also highly protein-bound).
What is the primary concern?
A. Decreased absorption of Drug A
B. Increased free fraction of Drug A leading to toxicity
C. Reduced renal excretion of Drug B
D. Competitive inhibition of CYP450
,Correct Answer: B
Rationale: When two highly protein-bound drugs compete for binding sites, one may be displaced,
increasing the free (active) fraction of the drug in the plasma, potentially leading to toxicity.
4. Which phase of FDA drug approval involves post-marketing surveillance?
A. Phase I
B. Phase II
C. Phase III
D. Phase IV
Correct Answer: D
Rationale: Phase IV occurs after the drug is approved and on the market. It involves monitoring for long-
term adverse effects and effectiveness in larger populations.
5. An NP prescribes a medication that is a CYP450 3A4 inhibitor. What effect will this have on a
concomitant medication metabolized by 3A4?
A. Decreased levels of the concomitant medication
B. Increased levels of the concomitant medication
C. No effect on metabolism
D. Increased excretion of the concomitant medication
Correct Answer: B
Rationale: Inhibitors slow down the metabolism of substrates. If Drug A inhibits the enzyme that
metabolizes Drug B, levels of Drug B will rise, increasing toxicity risk.
6. What is the definition of "off-label" prescribing?
A. Prescribing a generic version of a brand drug
B. Prescribing a drug for a use not approved by the FDA
C. Prescribing a controlled substance without a DEA number
D. Prescribing a drug past its expiration date
Correct Answer: B
Rationale: Off-label prescribing involves using an FDA-approved medication for an indication, dosage, or
population not specified in the official labeling. It is legal and common in NP practice if supported by
evidence.
7. Which route of administration bypasses the first-pass effect completely?
,A. Oral
B. Sublingual
C. Intravenous
D. Rectal
Correct Answer: C
Rationale: Intravenous administration delivers the drug directly into systemic circulation, bypassing the
GI tract and liver first-pass metabolism entirely. Sublingual bypasses most, but IV bypasses all.
8. A patient has a GFR of 25 mL/min. How does this affect drug prescribing?
A. Increase doses of renally excreted drugs
B. Decrease doses or extend intervals of renally excreted drugs
C. Avoid all oral medications
D. No adjustment needed for antibiotics
Correct Answer: B
Rationale: A GFR of 25 indicates severe renal impairment. Drugs excreted by the kidneys will
accumulate, requiring dose reduction or interval extension to prevent toxicity.
9. What is the primary goal of Phase I clinical trials?
A. Efficacy in disease state
B. Safety and dosage in healthy volunteers
C. Comparison with standard treatment
D. Long-term side effect monitoring
Correct Answer: B
Rationale: Phase I trials primarily assess safety, tolerability, and pharmacokinetics in a small group of
healthy volunteers.
10. Which of the following is a Black Box Warning?
A. A warning about minor side effects
B. The FDA's strongest warning regarding serious risks
C. A warning for pediatric use only
D. A warning regarding cost
Correct Answer: B
, Rationale: A Black Box Warning is the strictest warning put in the labeling of prescription drugs by the
FDA, indicating a significant risk of serious or life-threatening adverse effects.
11. Bioequivalence between two drugs means:
A. They contain the same inactive ingredients
B. They have the same bioavailability and rate of absorption
C. They are manufactured by the same company
D. They cost the same amount
Correct Answer: B
Rationale: Bioequivalent drugs have the same rate and extent of absorption of the active ingredient,
resulting in similar therapeutic effects.
12. A patient develops a rash after starting Penicillin. This is an example of:
A. A side effect
B. An allergic reaction (Idiosyncratic)
C. A teratogenic effect
D. A drug-drug interaction
Correct Answer: B
Rationale: A rash following penicillin is typically an immunologic allergic reaction, distinct from a
predictable side effect like nausea.
13. Which factor most influences drug distribution in the elderly?
A. Increased total body water
B. Decreased body fat
C. Decreased albumin levels
D. Increased liver mass
Correct Answer: C
Rationale: Elderly patients often have decreased serum albumin, leading to less protein binding and
higher levels of free drug for highly bound medications.
14. What is the "half-life" of a drug?
A. Time to reach peak concentration
B. Time required to eliminate 50% of the drug from the body
C. Time until the drug becomes ineffective
